Dr. Dmitry Kravtsov, M.D., Vice President of Research & Development at Vanessa Research, Inc. (VRI), discusses the white paper "Addressing the Microvillus Inclusion Disease Knowledge Gap – A Comprehensive Case Analysis". MVID is a rare genetic disease that afflicts infants with very severe diarrhea. Shylicine™ is the first-ever drug developed to treat microvillus inclusion disease.
Visit www.hpr.fm to listen to more podcast episodes about health.
